Status:
TERMINATED
Celebrex Total Knee Arthroplasty Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Osteoarthritis
Pain
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study will investigate the benefits of administering celecoxib (Celebrex), a selective cyclooxygenase -2 (COX-2) inhibitor, in treating osteoarthritis (OA) subjects undergoing elective unilateral...
Eligibility Criteria
Inclusion
- The subject is a male or female 18 years or older with osteoarthritis of the knee scheduled to undergo elective unilateral primary total knee arthroplasty because of OA, performed under a standardized regimen of anesthesia and procedure.
Exclusion
- Subject has a history of inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing spondylitis) other than osteoarthritis.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00359151
Start Date
November 1 2006
End Date
July 1 2007
Last Update
March 3 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aurora, Colorado, United States, 80012
2
Pfizer Investigational Site
Englewood, Colorado, United States, 80110
3
Pfizer Investigational Site
Chicago, Illinois, United States, 60612
4
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19107